ATE44156T1 - Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie. - Google Patents
Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie.Info
- Publication number
- ATE44156T1 ATE44156T1 AT84111048T AT84111048T ATE44156T1 AT E44156 T1 ATE44156 T1 AT E44156T1 AT 84111048 T AT84111048 T AT 84111048T AT 84111048 T AT84111048 T AT 84111048T AT E44156 T1 ATE44156 T1 AT E44156T1
- Authority
- AT
- Austria
- Prior art keywords
- preparation
- iii complex
- thrombous
- embolism
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 229960005348 antithrombin iii Drugs 0.000 title abstract 3
- 208000005189 Embolism Diseases 0.000 title 1
- 102000004411 Antithrombin III Human genes 0.000 abstract 2
- 108090000935 Antithrombin III Proteins 0.000 abstract 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 2
- 229960002897 heparin Drugs 0.000 abstract 2
- 229920000669 heparin Polymers 0.000 abstract 2
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 238000010668 complexation reaction Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/536,072 US4689323A (en) | 1983-09-26 | 1983-09-26 | Covalently bound heparin--antithrombin-III complex |
| EP84111048A EP0137356B1 (de) | 1983-09-26 | 1984-09-17 | Kovalent gebundener Heparin-Antithrombin III-Komplex, Verfahren zu dessen Herstellung und seine Verwendung zur Behandlung von Thrombusembolie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE44156T1 true ATE44156T1 (de) | 1989-07-15 |
Family
ID=24137020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT84111048T ATE44156T1 (de) | 1983-09-26 | 1984-09-17 | Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4689323A (de) |
| EP (1) | EP0137356B1 (de) |
| AT (1) | ATE44156T1 (de) |
| AU (1) | AU573262B2 (de) |
| CA (1) | CA1240264A (de) |
| DE (1) | DE3478749D1 (de) |
| ES (1) | ES8604623A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE98814T1 (de) | 1982-06-10 | 1984-06-20 | Kabivitrum Ab, 11287 Stockholm | Antithrombin-heparin komplex. |
| US5707604A (en) * | 1986-11-18 | 1998-01-13 | Access Pharmaceuticals, Inc. | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles |
| US5672334A (en) * | 1991-01-16 | 1997-09-30 | Access Pharmaceuticals, Inc. | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans |
| US4900723A (en) * | 1988-04-29 | 1990-02-13 | E. R. Squibb & Sons, Inc. | Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination |
| DK148890D0 (da) * | 1990-06-19 | 1990-06-19 | Novo Nordisk As | Farmaceutisk praeparat |
| US5599677A (en) * | 1993-12-29 | 1997-02-04 | Abbott Laboratories | Immunoassays for prostate specific antigen |
| US6106866A (en) * | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
| US6491965B1 (en) * | 1995-11-30 | 2002-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US6562781B1 (en) * | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
| AT405905B (de) * | 1997-03-25 | 1999-12-27 | Immuno Ag | Neue verwendung von antithrombin iii |
| JP3096737B1 (ja) * | 1999-07-19 | 2000-10-10 | 工業技術院長 | ヒト・動物細胞培養液 |
| ES2296914T3 (es) * | 2001-01-26 | 2008-05-01 | The General Hospital Corporation | Farmacos de serpina para el tratamiento de la infeccion por vih y metodo de uso de los mismos. |
| US8563693B2 (en) * | 2001-01-26 | 2013-10-22 | Acceleration Biopharmaceuticals, Inc. | Method of treating human immunodeficiency virus infection in a mammal comprising administering heparin-activated antithrombin III |
| CA3171069A1 (en) * | 2020-04-04 | 2021-10-07 | Jessica C. CARDENAS | Method for reducing the occurrence of thrombosis or thromboembolism |
| CN120272568B (zh) * | 2025-06-11 | 2025-08-19 | 苏州良辰生物仪器试剂有限公司 | 抗凝血酶iii测定试剂盒及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4301153A (en) * | 1977-03-21 | 1981-11-17 | Riker Laboratories, Inc. | Heparin preparation |
| JPS6040859B2 (ja) * | 1977-07-27 | 1985-09-12 | 喜温 三浦 | 抗血栓性人工医療材料 |
| ATE12779T1 (de) * | 1980-09-30 | 1985-05-15 | Bayer Ag | Verfahren zur herstellung eines antithrombinheparin-komplexes sowie diesen komplex enthaltende pharmazeutische mischungen. |
| US4446126A (en) * | 1980-09-30 | 1984-05-01 | Cutter Laboratories, Inc. | Antithrombin-heparin complex and method for its production |
| DE3038163A1 (de) * | 1980-10-09 | 1982-05-06 | Boehringer Mannheim Gmbh, 6800 Mannheim | Thrombininhibitor, seine herstellung und verwendung |
-
1983
- 1983-09-26 US US06/536,072 patent/US4689323A/en not_active Expired - Lifetime
-
1984
- 1984-09-17 EP EP84111048A patent/EP0137356B1/de not_active Expired
- 1984-09-17 AT AT84111048T patent/ATE44156T1/de not_active IP Right Cessation
- 1984-09-17 DE DE8484111048T patent/DE3478749D1/de not_active Expired
- 1984-09-19 ES ES536055A patent/ES8604623A1/es not_active Expired
- 1984-09-21 CA CA000463807A patent/CA1240264A/en not_active Expired
- 1984-09-26 AU AU33568/84A patent/AU573262B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE3478749D1 (en) | 1989-07-27 |
| CA1240264A (en) | 1988-08-09 |
| US4689323A (en) | 1987-08-25 |
| EP0137356A3 (en) | 1986-05-14 |
| ES536055A0 (es) | 1986-02-01 |
| ES8604623A1 (es) | 1986-02-01 |
| AU3356884A (en) | 1985-04-04 |
| AU573262B2 (en) | 1988-06-02 |
| EP0137356B1 (de) | 1989-06-21 |
| EP0137356A2 (de) | 1985-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE44156T1 (de) | Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie. | |
| EP0147761A3 (en) | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer | |
| DE69230112D1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| DE69830185D1 (de) | Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen | |
| DE3684190D1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
| ATE322283T1 (de) | Transdermale verwendung von sekretin zur behandlung von autismus | |
| DE69012591D1 (de) | Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen. | |
| ATA164884A (de) | Verfahren zur herstellung von festen, zweiphasigen nifedipinhaltigen arzneimittelzubereitungen | |
| DE69428268D1 (de) | Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma | |
| DE3587266D1 (de) | Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut. | |
| DE69320646D1 (de) | Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff | |
| ATE202709T1 (de) | Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten | |
| ATE172117T1 (de) | Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten | |
| DE69024053D1 (de) | Behandlung zur ermässigung von ödem und muskelschäden. | |
| DE3068820D1 (en) | Pharmaceutical preparations | |
| ATE122100T1 (de) | Humaner monoklonaler antikörper und diesen enthaltende arzneimittelzusammensetzung zur behandlung von pseudomonasinfektionen. | |
| DE69424415D1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
| SU1263246A1 (ru) | Способ лечени острого стоматита | |
| SE9101341D0 (sv) | New medicinal use | |
| RU2014020C1 (ru) | Способ лечения стилоидита | |
| DE69732851D1 (de) | Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren | |
| RU95118494A (ru) | Способ лечения летней формы псориаза | |
| RU96122672A (ru) | Эхинамакс. способ лечения астенических состояний при физиогенных дезадаптациях | |
| UA10221A (uk) | Спосіб лікування рецидивного бронхіту у дітей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |